WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Suburban Detroit police fatally shoot man who pointed gun at themEvacuation notice lifted in Utah town downstream from cracked damThe US and UK restrict the trade of RussianPope will travel to Indonesia, Papua New Guinea, East Timor and Singapore in longest trip of papacyRoberto Cavalli, Italian fashion designer, dies at 83Berlin zoo celebrates the 67th birthday of Fatou, believed to be the world's oldest gorillaFaced with possibly paying for news, Google removes links to California news sites for some usersPoland calls aid worker's killing in Gaza a murder, wants further investigationGerman parliament approves payment cards for asylumSome fear University of Michigan proposed policy on protests could quell free speech efforts
2.3492s , 6496.15625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,World Watch news portal